ACET Stock Analysis: Buy, Sell, or Hold?
ACET - Adicet Bio, Inc. Common Stock
$7.70
-0.28 (-3.51%)
▼
5d:
-9.84%
30d:
-12.7%
90d:
+926.67%
HOLD
LOW Confidence
Last Updated: February 3, 2026
Earnings: Mar 05, 2026
28d
Get Alerted When ACET Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: ACET shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: ACET shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: ACET is currently trading at $7.70, which is considered fair relative to its 30-day fair value range of $5.55 to $9.70.
Technical Outlook: Technically, ACET is in a strong uptrend. The price is currently testing key support at $7.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.50 (+698.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, ACET is in a strong uptrend. The price is currently testing key support at $7.64. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.5% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (21th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $61.50 (+698.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$5.55 -
$9.70
Company Quality Score
56/100
(HOLD)
Options IV Signal
21th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 21th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.5%)
- BULLISH: Trading 698.7% below Wall St target ($61.50)
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$5.55 -
$9.70
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$1.32
(17.1%)
Support & Resistance Levels
Support Level
$7.64
Resistance Level
$9.00
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-0.69
Wall Street Target
$61.50
(+698.7%)
Revenue Growth (YoY)
-100.0%
Last updated: February 03, 2026 8:04 PM ET
Data refreshes hourly during market hours. Next update: 9:04 PM
Data refreshes hourly during market hours. Next update: 9:04 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ACET showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Featured in Portfolios
ACET is a key holding in these high-performance investment strategies.
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 67 BUY |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 56 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 50 HOLD |
